Dynavax TechnologiesDVAX
About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Employees: 405
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
68% more call options, than puts
Call options by funds: $8.17M | Put options by funds: $4.87M
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 80
16% more capital invested
Capital invested by funds: $1.44B [Q3] → $1.67B (+$224M) [Q4]
2% more funds holding
Funds holding: 250 [Q3] → 254 (+4) [Q4]
0.32% more ownership
Funds ownership: 98.97% [Q3] → 99.29% (+0.32%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JMP Securities Roy Buchanan 21% 1-year accuracy 5 / 24 met price target | 221%upside $31 | Market Outperform Maintained | 7 May 2025 |
Goldman Sachs Paul Choi 56% 1-year accuracy 9 / 16 met price target | 3%upside $10 | Sell Maintained | 17 Apr 2025 |
Citizens Capital Markets Jason Butler 24% 1-year accuracy 9 / 38 met price target | 241%upside $33 | Market Outperform Maintained | 21 Feb 2025 |
HC Wainwright & Co. Edward White 17% 1-year accuracy 22 / 129 met price target | 221%upside $31 | Buy Reiterated | 21 Feb 2025 |
Financial journalist opinion
Based on 13 articles about DVAX published over the past 30 days









